Vanguard Global Advisers’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.8M Buy
41,623
+4,206
+11% +$452K ﹤0.01% 806
2026
Q2
$3.25M Sell
37,417
-547
-1% -$33K ﹤0.01% 969
2026
Q1
$1.53M Buy
+37,964
New +$1.42M ﹤0.01% 1378

Other funds holding CORT

Vanguard Global Advisers's CORT Position: Q3 2026 in Review

Vanguard Global Advisers increased its Corcept Therapeutics (CORT) stake by 11% in Q3 2026, buying an estimated $452K and bringing the position to 41,623 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #806.

Vanguard Global Advisers first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 463 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Vanguard Global Advisers held 41,623 shares of Corcept Therapeutics worth $4.8M as of Q3 2026.
  • Vanguard Global Advisers bought 4,206 Corcept Therapeutics shares in Q3 2026, an estimated $452K.
  • Corcept Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #806 holding.
  • Vanguard Global Advisers first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 463 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.